UroGen Pharma (NASDAQ:URGN) Issues Quarterly Earnings Results

UroGen Pharma (NASDAQ:URGN) announced its quarterly earnings data on Wednesday. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29, RTT News reports. The company had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the firm posted ($0.68) EPS.

UroGen Pharma Price Performance

UroGen Pharma stock traded down $0.04 during midday trading on Thursday, reaching $12.20. 190,909 shares of the stock were exchanged, compared to its average volume of 502,450. The company’s fifty day moving average is $12.82 and its 200-day moving average is $14.20. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15. The firm has a market cap of $286.09 million, a PE ratio of -3.73 and a beta of 1.12. UroGen Pharma has a 52 week low of $10.60 and a 52 week high of $20.70.

Analysts Set New Price Targets

URGN has been the topic of several research reports. Guggenheim initiated coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma presently has a consensus rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.